Canada Markets closed

Arch Therapeutics, Inc. (ARTH)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.1076-0.0024 (-2.23%)
At close: 12:41PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close0.1074
Open0.1100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.1050 - 0.1100
52 Week Range0.0580 - 0.1900
Volume4,345
Avg. Volume260,229
Market Cap25.508M
Beta (5Y Monthly)-0.74
PE Ratio (TTM)N/A
EPS (TTM)-0.0280
Earnings DateDec. 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est3.00
  • GlobeNewswire

    Clinical Evaluation Finds Arch Therapeutics’ AC5® Advanced Wound System Effective in Healing Complex Chronic Wounds in Patients with Previously Unsuccessful Treatments and Significant Comorbidities

    AC5® Advanced Wound System demonstrated notable improvement in healing after only 3 to 6 applications—with only weekly clinic visits and reapplicationFRAMINGHAM, Mass., Jan. 06, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced a study of its proprietary adaptive self-assembling barrier scaffold (aSABS) and peptide technology, AC5® Advanced Wound System, d

  • GlobeNewswire

    Arch Therapeutics Announces Appointment of Guy Fish to the Board

    Brings Broad Industry Experience in Strategy and ExecutionFRAMINGHAM, Mass., Jan. 04, 2022 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced the appointment of Guy Fish, M.D. to its Board of Directors. Dr. Fish is a proven leader in the medical industry with deep experience and expertise as an operator, investor, board member and advisor to numerous healthcare

  • GlobeNewswire

    Arch Therapeutics Granted Federal Supply Schedule and General Supply Administration Contracts for AC5® Advanced Wound System

    Significantly Expands Access to Include All Federal Government AgenciesFRAMINGHAM, Mass., Dec. 13, 2021 (GLOBE NEWSWIRE) -- Arch Therapeutics, Inc. (OTCQB: ARTH) (“Arch” or the “Company”), a marketer and developer of novel self-assembling wound care and biosurgical devices, today announced that in partnership with Lovell Government Services, Arch’s AC5® Advanced Wound System (“AC5®”) has been added to the Federal Supply Schedule (“FSS”) and General Services Administration (“GSA”) contracts, and